LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Finnish Gastric Cancer Biomarker Tests to Be used in Large Chinese Screening Study

By LabMedica International staff writers
Posted on 11 Aug 2015
Print article
The GastroPanel comprises four biomarker ELISA kits
The GastroPanel comprises four biomarker ELISA kits (Photo courtesy of BIOHIT Healthcare OY)
A panel of tests produced by a Finnish biomedical company that assess gastric cancer risk will be used in a large screening study of asymptomatic persons in China.

The Biohit Oyj (Helsinki, Finland) GastroPanel is a set of four ELISA kits that diagnose Helicobacter pylori infection and atrophic gastritis by determining levels of the biomarkers pepsinogen I (PGI), pepsinogen II (PGII), gastrin-17 (G-17), and H. pylori antibodies. The tests are noninvasive and performed upon small blood samples.

The gastric cancer risk screening study was organized by the China Health Promotion Foundation, a public organization managed by the Chinese Ministry of Health. Testing of approximately 500,000 40–80-year-old asymptomatic persons with GastroPanel assays will be conducted at fifty to one hundred primary healthcare centers across China. Collection of samples began in the summer of 2015, and data collection and analysis, including evaluation, are planned to be finalized by the end of 2016.

Semi Korpela, CEO of Biohit Oyj, said, "This is an outstanding opening for GastroPanel biomarkers in the screening of asymptomatic subjects to disclose the risk groups for gastric cancer and vitamin B12 malabsorption among other things. Gastric cancer is the leading cause of cancer related mortality in China. The use of the very informative GastroPanel for the screening of gastric cancer risk offers the possibility for the prevention and early detection of stomach cancers. Based on correct diagnosis, screening reduces sick leaves and loss of labor input, as well as self-medication with its associated risks. Early detection of risk conditions for gastric cancer and vitamin and mineral deficiencies saves healthcare costs and human suffering as well."

Related Links:

Biohit Oyj


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more